Analyzing Grifols (NASDAQ:GRFS) & Parabilis Medicines (NASDAQ:PBLS)

Parabilis Medicines (NASDAQ:PBLS) and Grifols (NASDAQ:GRFS) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.

Earnings and Valuation

This table compares Parabilis Medicines and Grifols”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parabilis Medicines	N/A	N/A	-$145.89 million	($2.13)	-13.47
Grifols	$8.51 billion	0.64	$454.82 million	$0.19	42.32

Grifols has higher revenue and earnings than Parabilis Medicines. Parabilis Medicines is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Parabilis Medicines and Grifols, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parabilis Medicines	1	1	5	1	2.75
Grifols	1	2	0	0	1.67

Parabilis Medicines presently has a consensus price target of $41.25, suggesting a potential upside of 43.73%. Grifols has a consensus price target of $9.00, suggesting a potential upside of 11.94%. Given Parabilis Medicines’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Parabilis Medicines is more favorable than Grifols.

Profitability

This table compares Parabilis Medicines and Grifols’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Parabilis Medicines	N/A	N/A	N/A
Grifols	5.54%	6.21%	2.39%

Summary

Grifols beats Parabilis Medicines on 6 of the 10 factors compared between the two stocks.

About Parabilis Medicines

Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.

About Grifols

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.